Abstract:The field of oncology has transformed in recent years, with treatments shifting from traditional surgical resection and radiation therapy to more diverse and customized approaches, one of which is immunotherapy. ICD (immunogenic cell death) belongs to a class of regulatory cell death modalities that reactivate the immune response by facilitating the interaction between apoptotic cells and immune cells and releasing specific signaling molecules, and DAMPs (damage-associated molecular patterns). The inducers of ICD can elevate the expression of specific proteins to optimize the TME (tumor microenvironment). The use of nanotechnology has shown its unique potential. Nanomaterials, due to their tunability, targeting, and biocompatibility, have become powerful tools for drug delivery, immunomodulators, etc., and have shown significant efficacy in clinical trials. In particular, these nanomaterials can effectively activate the ICD, trigger a potent anti-tumor immune response, and maintain long-term tumor suppression. Different types of nanomaterials, such as biological cell membrane-modified nanoparticles, self-assembled nanostructures, metallic nanoparticles, mesoporous materials, and hydrogels, play their respective roles in ICD induction due to their unique structures and mechanisms of action. Therefore, this review will explore the latest advances in the application of these common nanomaterials in tumor ICD induction and discuss how they can provide new strategies and tools for cancer therapy. By gaining a deeper understanding of the mechanism of action of these nanomaterials, researchers can develop more precise and effective therapeutic approaches to improve the prognosis and quality of life of cancer patients. Moreover, these strategies hold the promise to overcome resistance to conventional therapies, minimize side effects, and lead to more personalized treatment regimens, ultimately benefiting cancer treatment.

Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; Combination of Oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction

Emerging role of immunogenic cell death in cancer immunotherapy: Advancing next-generation CAR-T cell immunotherapy by combination

Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy

Combining Oncolytic Viruses with Chimeric Antigen Receptor T Cell Therapy

Oncolytic virus enhanced CAR T cell therapy in killing solid tumors

Immunogenic cell death-based oncolytic virus therapy: A sharp sword of tumor immunotherapy

Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment

Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment

Immunogenic cell death-based cancer vaccines: promising prospect in cancer therapy

Immunogenic cell death and its emerging inducers:the next generation immunotherapy

Chimeric Antigen Receptor- and Natural Killer Cell Receptor-Engineered Innate Killer Cells in Cancer Immunotherapy

Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment

Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies

Oncolytic virus–mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice

Targeting immunogenic cell death in cancer

Investigating chimeric antigen receptor T cell therapy and the potential for cancer immunotherapy (Review)

Bioorthogonal Oncolytic-Virus Nanovesicles Combined Bio-Immunotherapy with CAR-T Cells for Solid Tumors.

The emerging field of oncolytic virus-based cancer immunotherapy

Nanomaterials: leading immunogenic cell death-based cancer therapies

Enhancing Cancer Immunotherapy: A Novel Approach through the Integration of Oncolytic Virotherapy with CAR-T and NK Cell Therapies

Trial watch: chemotherapy-induced immunogenic cell death in oncology